Prognostic Characteristics of Primary Squamous Cell Carcinoma of the Thyroid: A National Cancer Database Analysis.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
11
8
2019
medline:
25
11
2020
entrez:
11
8
2019
Statut:
ppublish
Résumé
Primary squamous cell carcinoma of the thyroid (ThySCC) is a rare cancer, primarily described only in case reports. We aimed to characterize the prognosis of ThySCC and compare its oncologic behavior to other thyroid malignancies. The National Cancer Database was queried to identify patients with ThySCC, papillary, tall cell variant, poorly differentiated (PDTC), and anaplastic (ATC) subtypes of thyroid cancer treated from 2004 to 2015. Demographics, tumor characteristics, and treatments were compared by tumor type and assessed to identify independent predictors of overall survival (OS). Of 123,684 patients included, 314 had ThySCC. ThySCC patients had a 5-year OS of 17.7%, more closely resembling ATC (8.3%) than PDTC or PTC. ThySCC and ATC patients had similar demographics, except ThySCC patients who were younger (68.0 vs. 70.2 years, p < 0.01). ThySCC tumors were smaller (mean 53.5 ± 45.7 vs. 69.5 ± 75.2 mm) with less frequent extrathyroidal extension (ETE) (64.0% vs. 73.8%), lymphovascular invasion (8.3% vs. 12.3%), and positive margins (22.0% vs. 28.3%) compared to ATCs (p < 0.05). ETE [HR 3.1 (95% CI 1.5-6.4), p < 0.05] and lymph node metastases [HR 2.2 (95% CI 1.2-4.0) p < 0.05] were independently associated with worse OS for ThySCC patients. Both ThySCC and ATC patients had similar surgical success rates, with R1 resection possible in 37.3% versus 35.0% of patients, respectively (p < 0.05). However, in contrast to ATC patients, adjuvant therapy was not associated with improved OS for ThySCC patients after complete resection. ThySCC has a poor prognosis, similar to ATC, but with fewer aggressive features and no apparent survival benefit with adjuvant therapy after complete macroscopic surgical resection.
Sections du résumé
BACKGROUND
Primary squamous cell carcinoma of the thyroid (ThySCC) is a rare cancer, primarily described only in case reports. We aimed to characterize the prognosis of ThySCC and compare its oncologic behavior to other thyroid malignancies.
METHODS
The National Cancer Database was queried to identify patients with ThySCC, papillary, tall cell variant, poorly differentiated (PDTC), and anaplastic (ATC) subtypes of thyroid cancer treated from 2004 to 2015. Demographics, tumor characteristics, and treatments were compared by tumor type and assessed to identify independent predictors of overall survival (OS).
RESULTS
Of 123,684 patients included, 314 had ThySCC. ThySCC patients had a 5-year OS of 17.7%, more closely resembling ATC (8.3%) than PDTC or PTC. ThySCC and ATC patients had similar demographics, except ThySCC patients who were younger (68.0 vs. 70.2 years, p < 0.01). ThySCC tumors were smaller (mean 53.5 ± 45.7 vs. 69.5 ± 75.2 mm) with less frequent extrathyroidal extension (ETE) (64.0% vs. 73.8%), lymphovascular invasion (8.3% vs. 12.3%), and positive margins (22.0% vs. 28.3%) compared to ATCs (p < 0.05). ETE [HR 3.1 (95% CI 1.5-6.4), p < 0.05] and lymph node metastases [HR 2.2 (95% CI 1.2-4.0) p < 0.05] were independently associated with worse OS for ThySCC patients. Both ThySCC and ATC patients had similar surgical success rates, with R1 resection possible in 37.3% versus 35.0% of patients, respectively (p < 0.05). However, in contrast to ATC patients, adjuvant therapy was not associated with improved OS for ThySCC patients after complete resection.
CONCLUSIONS
ThySCC has a poor prognosis, similar to ATC, but with fewer aggressive features and no apparent survival benefit with adjuvant therapy after complete macroscopic surgical resection.
Identifiants
pubmed: 31399796
doi: 10.1007/s00268-019-05098-5
pii: 10.1007/s00268-019-05098-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
348-355Références
Eur J Surg Oncol. 2002 Feb;28(1):42-5
pubmed: 11869012
J Laryngol Otol. 2011 Jan;125(1):3-9
pubmed: 20950510
Eur J Surg Oncol. 1999 Dec;25(6):606-9
pubmed: 10556008
Iran J Otorhinolaryngol. 2018 Jan;30(96):65-68
pubmed: 29387667
Case Rep Oncol Med. 2017;2017:4276435
pubmed: 29158933
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Med Care. 2015 Sep;53(9):e65-72
pubmed: 23703645
J Surg Oncol. 1988 Nov;39(3):175-8
pubmed: 3184953
Eur Ann Otorhinolaryngol Head Neck Dis. 2018 Aug;135(4):291-293
pubmed: 29914738
Am Surg. 1964 Apr;30:247-52
pubmed: 14149689
Otolaryngol Head Neck Surg. 2017 Jul;157(1):25-29
pubmed: 28397584
Pathol Int. 2012 Jan;62(1):43-8
pubmed: 22192803
Thyroid. 2006 Jan;16(1):89-93
pubmed: 16487020
J Surg Case Rep. 2014 Dec 08;2014(12):
pubmed: 25487371
Otolaryngol Head Neck Surg. 2019 Feb;160(2):284-294
pubmed: 30129822
J Surg Oncol. 2014 Jun;109(7):629-30
pubmed: 24464362
Endocr J. 2008 May;55(2):359-64
pubmed: 18379125
Nat Rev Endocrinol. 2017 Nov;13(11):644-660
pubmed: 28707679
Thyroid. 2011 May;21(5):493-9
pubmed: 21309723
J Surg Res. 2018 Mar;223:39-45
pubmed: 29433884
Head Neck. 2013 Oct;35(10):E299-303
pubmed: 23002023
Cancer Med. 2014 Oct;3(5):1396-403
pubmed: 24995699
Surgeon. 2007 Aug;5(4):249-51
pubmed: 17849961
Int J Surg Case Rep. 2017;37:36-40
pubmed: 28633125
Am J Surg. 1988 Jul;156(1):44-6
pubmed: 3394892
J Natl Compr Canc Netw. 2018 Dec;16(12):1429-1440
pubmed: 30545990